Weight loss advertising in 2026: what Meta, TikTok and Google allow for GLP-1 telehealth programs, the FDA crackdown, and compliant ad examples.
The short answer
Weight loss advertising is allowed on Meta, Google and Pinterest for weight-management programs framed around ongoing care, and heavily restricted for prescription GLP-1 drugs. Ads may describe a physician-guided program. They may not promise results, show before-and-after bodies or imply a compounded drug equals an FDA-approved one. The FDA sent 30 warning letters over such claims in March 2026.
Key takeaways
Weight loss is the most heavily reviewed consumer category on every ad platform, and GLP-1 medication has made it more so. Meta reads the copy for personal-attribute language. TikTok bans prescription medicine ads through self-serve. Google reviews the landing page for anything that mentions semaglutide. And since September 2025 the FDA has been sending warning letters to telehealth companies at a pace it says exceeds the whole previous decade.
This page covers what a weight loss ad can say and show, platform by platform, what the FDA is actually citing in its letters, and how to build creative and creator content that clears review and keeps running. Examples included. Legal advice not included; your counsel reads the claims sheet.
A weight loss ad may describe a program, its structure, who runs it and who is eligible. It may not promise a result, imply the result is easy or guaranteed, show a body transformation, or claim a medication does something its approval or its evidence does not support. That is the shared core of FTC law, FDA rules and the ad policies at Meta, Google and TikTok.
The FTC has pursued weight loss advertising for decades and publishes consumer guidance on the claims it considers red flags: losing weight without diet or exercise, losing a specific amount in a specific time regardless of what you eat, permanent results, a product that works for everyone. Any of those in your ad needs evidence the FTC would accept, and for most products that evidence does not exist.
Meta's health policy allows ads that help people treat or manage a condition and prohibits ads that claim to cure, heal or eliminate it. Its personal-attributes rule prohibits copy that implies Meta knows something about the viewer's health or weight. Its body-image rules prohibit content that generates negative self-perception, which is how before-and-after creative gets classified. Meta has also been disabling custom audiences and conversion events with health-related names, and restricting lower-funnel optimization for health advertisers, so the account setup gets reviewed as well as the ad.
A great deal, in practice. The clinician. The program structure. Eligibility and the consultation. Side effects stated plainly. Pricing and what is included. A patient describing the experience of the program without quoting a number. Routine content around food, movement and check-ins. This is the creative library compliant weight-management brands run on, and it is enough to fill a hundred concepts.
It depends on who you are and what the product is. A pharmaceutical manufacturer can advertise its approved GLP-1 drug on Google in the United States, Canada and New Zealand with Google certification, and on TV and other channels under FDA prescription-drug advertising rules. A telehealth company offering compounded semaglutide or tirzepatide is in a different position, and the options narrow.
Telehealth weight-management programs can advertise if the creative manages rather than cures, avoids personal-attribute copy and body imagery, and does not name or imply a branded drug. Meta has faced public scrutiny over misleading weight loss drug ads on its platforms, and review has tightened as a result.
Prescription drug advertising is restricted to certified pharmaceutical manufacturers. Telehealth providers can advertise their service, and Google reviews the landing page closely for GLP-1 terms. Offering prescription drugs without a prescription is an egregious violation that leads to permanent suspension.
Prescription medicine is prohibited through TikTok's self-serve ads in most markets, and its weight management policy age-gates all weight content to 18+ and prohibits claims of easy or guaranteed loss, loss without diet or exercise, and body shaming. For a telehealth GLP-1 brand, paid TikTok is effectively closed without a sales relationship. Organic and creator content remains open, with the same claim rules.
Pinterest carries a narrow, explicit exception: approved healthcare advertisers in the US and Canada may promote prescription GLP-1 medication. It is the only major platform with that carve-out today.
Open, with publisher-level review. This is where a lot of telehealth weight-management spend sits, on contextual placement rather than health-interest targeting.
None of the above overrides the FDA. A compliant Meta ad that links to a website making the claims described in the next section still draws a warning letter.
On 3 March 2026 the FDA announced 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1 products on their websites. It was the second batch since the agency launched a crackdown on direct-to-consumer pharmaceutical advertising in September 2025. Over those six months, the FDA said it had sent thousands of letters to pharmaceutical and telehealth firms, more than in the entire preceding decade. Further letters followed in June 2026.
The FDA's own guidance for telehealth companies, updated June 2026, lists the claims it considers false or misleading:
The June 2026 letters quote specific website language: "clinically studied ingredients", "proven to lose weight effectively", and sourcing from "FDA approved pharmacies". Each of those phrases appears on a large number of telehealth landing pages right now.
The FDA reviews the website, and the website is where every ad lands. A media team can clear Meta review with a careful ad and still be the reason the company receives a letter, because the landing page says what the ad was careful not to. Claims review has to cover the destination, the checkout flow and the FAQ along with the creative. Companies have fifteen business days to respond to a letter, and the FDA has said it is watching all media platforms.
Start from what Meta will clear and build backwards, rather than starting from the transformation story and trimming. Six rules, each learned from a rejection.
The first frame is a doctor, a consultation screen, a plan on a phone. Torsos, scales and jeans stay out of frame.
"A physician-guided weight management program" clears. "Struggling to lose weight?" is personal-attribute copy and fails. "I started a program in March, here is what the first month was like" from a real patient, with disclosure, clears.
This single word swap is the difference in a large share of rejections.
"Lose 20 lbs in 8 weeks" is out unless that is the typical result in your own data and you can show it. "Weekly check-ins with your care team" is a number you can stand behind.
Ads that name semaglutide, tirzepatide or a brand-name drug invite both platform review and FDA attention. Describe the program. Let the consultation cover the medication.
Audience names, pixel events and conversion labels with health terms in them get disabled. Name them by funnel stage instead.
Clinician explainers. Program walkthroughs on a phone screen. Eligibility quiz previews. Patients describing the experience (the first week, side effects, the check-in cadence) without outcome numbers. Food and movement routine content. Pricing transparency. Twenty to thirty of these live and refreshed weekly is what holds performance on Meta in this category. The Facebook ad library guide shows how to study what competitors are running before you brief.
TikTok and Google apply different rules to weight loss advertising, and both are stricter than Meta for a GLP-1 brand.
TikTok's weight management policy requires 18+ targeting for all weight content and prohibits references to unrealistic loss, claims that a product works without diet or exercise, suggestions that loss is easy or guaranteed, body shaming, the idea of an ideal body type, and any link between appearance and confidence or success. Prescription medicine ads are prohibited through self-serve in most markets. Weight loss supplements and meal replacements are allowed only in select regions with local licensing.
TikTok has also been dealing with a wave of unregulated "GLP-1 patches" and knockoff products spreading through organic content and TikTok Shop in 2026, which has drawn press coverage and made the platform more conservative, not less, about anything weight-related. Expect enforcement to tighten.
What works: organic and creator content about the experience of a supervised program, food and routine content, clinician Q&A. Spark Ads on posts that already performed organically, with the same claim rules.
Google allows weight-management program advertising and reviews the landing page. Pages that mention GLP-1 drugs are read closely for prescription-drug promotion, which only certified manufacturers may do. Weight loss supplement ads follow the healthcare and unapproved substances policies, with disapproval most often tied to landing page claims. YouTube inherits the same rules, and a pre-roll is not a workaround.
Search intent is strong in this category and mostly local ("weight loss program near me"). A search campaign that leads with a free consultation and a program page that makes no outcome promise is one of the more reliable placements available to a telehealth brand.
Creator content sells weight-management programs because people believe a person before they believe a clinic. It is also the highest-risk lane in this category, for three reasons: the creator is improvising, the platform is watching weight content closely, and the FDA has said it is watching all media platforms for compounded drug claims.
That they joined a physician-guided program. What the consultation was like. What the first weeks felt like, including side effects, stated plainly. How the check-ins work. What it costs them. That the content is a paid partnership, in the video, up front.
That the medication is the same as a brand-name drug. That it is FDA-approved (compounded products are not). A number of pounds lost. That it was easy, or that it works without changing anything else. Anything about the viewer's body. Any mention of an "FDA-approved pharmacy".
Medical review of every script before filming. Verbatim approved lines and banned words in the contract. Frame-by-frame review of the delivered cut, including on-screen text and captions, before it posts. Monitoring after it posts, and a takedown clause. Disclosure in the video as well as the caption, per the FTC's Endorsement Guides.
A creator who has promoted a weight loss gummy, a detox tea or a "GLP-1 patch" in the last year is a risk regardless of how the new script reads, because their audience and their back catalog carry those claims. Screen the history along with the follower count. Strip bot engagement so you are not paying for reach that does not exist. Our influencer agent page walks through how Remy screens and briefs creators, and the influencer marketing compliance page covers the FTC disclosure and liability rules in full.
Four pairs. Same offer in each pair, different odds of surviving review.
Rejected: "Struggling to lose weight? Get Ozempic-style results without the wait." Personal-attribute copy, an implied brand-name comparison, and an outcome promise in one line.
Clears: "A physician-guided weight management program, built around your schedule." Describes the service. No body, no drug, no promise.
Rejected: side-by-side body photos, or a scale with a falling number.
Clears: a clinician on a video call, or the program's check-in screen on a phone.
Rejected: "I lost 34 pounds in three months and it was so easy." A number, a timeframe, and an easy-result claim.
Clears: "The first two weeks were rough on my stomach. The weekly check-ins were what kept me going." Real experience, a real limitation, no outcome claim. Disclosed as a paid partnership.
Rejected: "Clinically proven compounded semaglutide from FDA-approved pharmacies, the same as the brand at a fraction of the price." Four separate claims the FDA cited in its 2026 letters.
Clears: "Compounded medication prescribed if clinically appropriate, dispensed by a licensed pharmacy. Compounded drugs are not FDA-approved." Plain, accurate, survivable.
The pattern across all four: the compliant version describes the service and the experience, and the rejected version promises the outcome. That is the whole discipline, and it is the same discipline the FTC has asked for since long before GLP-1s existed.
QuickAds builds claims-safe performance creative for weight-management and telehealth brands, and runs the creator program through Remy, our influencer agent. The regulated-category workflow is the same one we use for CBD and supplements, tightened for this category.
Your counsel's approved claims (program description, eligibility language, side-effect statements, the compounded-drug disclosure) become a locked library. Concepts are assembled from that library and our hook library trained on 32M+ ads. Every asset, including creator cuts, is reviewed frame by frame against the claims sheet, with anything not ready flagged. The output is 100+ creatives a month at a 5 to 7 day turnaround, which is what it takes to keep twenty to thirty concepts live on Meta without repeating the one that got rejected.
On creators, Remy sources across Instagram, YouTube and TikTok, screens for bot engagement and for claims history, and negotiates from your handle under your cap. The compliance brief rides with every booking, and scripts route to your medical reviewer before filming.
What we do not do: medical, legal or regulatory review, and we do not write landing pages that make claims the FDA has already named in a warning letter. If a brief asks for a transformation story, we will say why it will not clear rather than soften it until it does.
Software from $299 per month. A managed program runs $2,000 to $5,000 per month depending on scope, in line with what a telehealth marketing agency or medspa marketing agency charges for the creative and creator layer alone. How the engagement runs is on its own page. Related pages: supplement marketing, CBD marketing, influencer marketing compliance, and creative as a service for how production runs.
Pharmaceutical manufacturers can advertise approved GLP-1 drugs on Google in the US, Canada and New Zealand with certification, and on other channels under FDA prescription-drug rules. Telehealth companies offering compounded GLP-1s can advertise their program on Meta and Google with restrictions (no cure claims, no body imagery, no brand-drug comparisons), on Pinterest as approved healthcare advertisers, and not through TikTok self-serve ads. The FDA reviews the landing page regardless of platform.
Compliant examples include a clinician explaining how a physician-guided program works, a walkthrough of the program's check-in app, an eligibility quiz preview, a patient describing the first weeks of a program without quoting a number, and routine content around food and movement. Rejected examples include before-and-after body photos, "lose 20 lbs in 8 weeks" headlines, second-person "struggling with your weight?" copy and any claim a compounded drug is the same as a brand-name one.
Lead with the clinician or program, never a body. Write in first or third person, never second. Use "manage", "treat" or "support", never "cure" or "eliminate". Drop any number you cannot substantiate as typical. Describe the program rather than naming a molecule or brand drug. Name audiences and conversion events by funnel stage, not health terms. Keep twenty to thirty concepts live and refresh weekly.
Remove personal-attribute copy, before-and-after imagery and outcome claims, and replace "cure" language with "manage" or "treat". Check the landing page, because Meta reads it too. Rename custom audiences and pixel events that contain health terms. Then request review with a short explanation of the changes. If the account has prior violations, expect a slower path and consider a compliance pre-read of every new concept.
In the US, the Federal Trade Commission enforces truth-in-advertising law for weight loss products and programs, the Food and Drug Administration enforces rules on drug and compounded drug promotion (and issued 30 warning letters to telehealth firms in March 2026), and state attorneys general bring cases under state consumer-protection law. Ad platforms enforce their own policies on top, up to permanent account suspension.
No. The FDA's June 2026 guidance to telehealth companies lists describing a compounded drug as a generic version of, or the same as, an FDA-approved drug among the claims it considers false or misleading, alongside "clinically proven" sameness claims and "FDA-approved pharmacy" sourcing claims. Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing. Those claims drew warning letters in 2026.
Only if you are the manufacturer. Ozempic is a branded prescription drug, and Google, Meta and TikTok limit branded prescription-drug promotion to the pharmaceutical company or its certified partners. A telehealth or med spa program cannot name Ozempic, Wegovy or Mounjaro in ad copy or compare a compounded drug to them. Describe your program instead, keep brand-drug names out of the ad, and check Google's prescription-drug-terms certification rules before using them as keywords.